We are pleased to have secured this term loan facility ahead of important anticipated catalysts, including gaining alignment with the FDA on the regulatory pathway of our pipeline candidate, VYD2311,” ...

Invivyd reported Q4 2024 revenue of $13.8 million, highlighting significant growth and ongoing development of COVID-19 treatments PEMGARDA and VYD2311. Invivyd, Inc. reported a net product revenue ...

March 20, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced financial ...

WALTHAM, Mass., March 26, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) is pleased to announce the appointment of Ajay Royan to its Board of Directors. Mr. Royan is a venture capitalist ...

In this article, we are going to take a look at where Invivyd, Inc. (NASDAQ:IVVD) stands against other best penny stocks to buy according to the media. On December 24, Global Advisors’ managing ...

In this article, we are going to take a look at where Invivyd, Inc. (NASDAQ:IVVD) stands against the other biotech stocks. No ...

2; affirms structural biology within Invivyd’s unique technology and reflects consistently stable epitope for pemivibart VYD2311 also demonstrates stable epitope and clinically meaningful in ...

WALTHAM, Mass., March 26, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) is pleased to announce the appointment of Ajay Royan to its Board of Directors. Mr. Royan is a venture capitalist ...

Invivyd has a fifty-two week low of $0.35 and a fifty-two week high of $4.74. Invivyd ( NASDAQ:IVVD – Get Free Report ) last issued its quarterly earnings data on Thursday, March 20th.

The latest analyst rating for Invivyd (NASDAQ:IVVD) was provided by HC Wainwright & Co., and Invivyd reiterated their buy rating. The last upgrade for Invivyd Inc happened on April 5, 2024 when ...

PEMGARDA™ (pemivibart) net product revenue of $13.8 million, representing 48% growth over Q3 2024 net product revenue of $9.3 million; full-year 2024 net product revenue totaled $25.4 million2024 year ...

This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer .